Blocking inflammation on the way: Rationale for CXCR2 antagonists for the treatment of COVID-19
Lars M. Koenig, Daniel F. R. Boehmer, Philipp Metzger, Max Schnurr, Stefan Endres, Simon Rothenfußer
Abstract
An exacerbated and unbalanced immune response may account for the severity of COVID-19, the disease caused by the novel severe acute respiratory syndrome (SARS) coronavirus 2, SARS-CoV-2. In this Viewpoint, we summarize recent evidence for the role of neutrophils in the pathogenesis of COVID-19 and propose CXCR2 inhibition as a promising treatment option to block neutrophil recruitment and activation.
Topics & Concepts
Coronavirus disease 2019 (COVID-19)PathogenesisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)InflammationBlocking (statistics)2019-20 coronavirus outbreakCoronavirusMedicineImmune systemImmunologyDiseaseVirologyInternal medicineInfectious disease (medical specialty)Computer scienceOutbreakComputer networkCOVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Neutrophil, Myeloperoxidase and Oxidative Mechanisms